演讲 & 视频

As several siRNA therapeutics move toward regulatory approval for cardiometabolic diseases, we expect demand for large-scale manufacturing to grow sharply over the coming decade. At TIDES Europe 2025 in Basel, our CTO, David Butler, spoke about the limitations of traditional solid-phase oligonucleotide synthesis in meeting that demand at the scale, cost, and level of sustainability […]

In this webinar, our CTO, David Butler presented the latest advancements in Hongene's chemoenzymatic ligation platform for oligonucleotides synthesis and provided strategic insights that will help researchers and companies navigate drug development process using the ligation technology.

This session emphasizes the ongoing innovation in scalable manufacturing technologies to meet the growing demand for RNA therapeutics, while addressing the product purity and environmental challenges associated with current methods.